Anadys Pharmaceuticals Announces Single Dose Safety and Pharmacokinetics Results for ANA598 in Healthy ...(LR7 agonist prodrug. The Company is also...),Health
| HOME >> MEDICINE >> TECHNOLOGY |
LR7 agonist prodrug. The Company is also developing ANA773 for the treatment of cancer.
Safe Harbor Statement
Statements in this press release that are not strictly historical in
nature constitute "forward-looking statements." Such statements include,
but are not limited to, references to (i) the belief that ANA598 is one of
the leading non-nucleoside polymerase inhibitors currently in development
for the treatment of HCV; (ii) the potential for ANA598 to be used in
combination with multiple other agents approved or under investigation for
hepatitis C; (iii) the potential for once-daily or twice-daily oral dosing
of ANA598; (iv) the level of plasma drug concentration of ANA598 predicted
to display antiviral potency; (v) the ability of Anadys to transition into
Phase II studies of ANA598 during 2009; and (vi) expectations regarding the
evolution of the market for HCV therapies. Such forward-looking statements
involve known and unknown risks, uncertainties and other factors, which may
cause Anadys' actual results to be materially different from historical
results or from any results expressed or implied by such forward-looking
statements. For example, the results of preclinical and early clinical
studies may not be predictive of future results, and Anadys cannot provide
any assurances that ANA598 and ANA773 will not have unforeseen safety
issues, will have favorable results in future clinical trials or will
receive regulatory approval. In addition, Anadys' results may be affected
by risks related to competition from other biotechnology and pharmaceutical
companies, its effectiveness at managing its financial resources, its
ability to successfully develop and market products, difficulties or delays
in its preclinical studies or clinical trials, difficulties or delays in
manufacturing its clinical trials materials, the scope and validity of
patent protection for its products, regulatory developments involving its
product candidates and its ability to obtai
'/>"/>
| SOURCE Anadys Pharmaceuticals, Inc. Copyright©2008 PR Newswire. All rights reserved |
Related medicine technology :
1. Anadys Pharmaceuticals to Present at the JMP Securities Healthcare Focus Conference
2. Anadys Pharmaceuticals Announces Successful Outcome of ANA598 Healthy Volunteer Study and Finalization of Study Design for Phase Ib Trial in HCV Patients
3. Anadys Pharmaceuticals Resumes Clinical Investigation of TLR7 Mechanism in HCV
4. Anadys Pharmaceuticals Initiates Phase I Clinical Trial of ANA598
5. Anadys Pharmaceuticals Presents Data on ANA598, a Non-Nucleoside Inhibitor of the HCV Polymerase, at the 21st International Conference on Antiviral Research
6. Anadys Pharmaceuticals Announces Positive Results for ANA598 in Animal Model of Chronic Hepatitis C Virus Infection
7. Anadys Pharmaceuticals Presents Preclinical Results on ANA598, a Non-Nucleoside Inhibitor of the NS5B Polymerase, at the 14th International Symposium on Hepatitis C Virus and Related Viruses
8. Rib-X Pharmaceuticals Reports Positive Phase 2 Study Results for Next Generation Oxazolidinone at 2008 ICAAC/IDSA Joint Meeting
9. Sequoia Pharmaceuticals Presents In Vitro and First-in-Human Data Supporting Further Development of SPI-256, a Novel Investigational Protease Inhibitor
10. Minster Pharmaceuticals Plc Announces Positive Results from Phase II Trial of Migraine with Aura
11. Addrenex Pharmaceuticals Initiates Phase 2 Trial on Its Novel Hypertension Drug, ADX415
| Copyright © 2003-2009 Bio-Medicine. All rights reserved. ABOUT | CONTACT US | DISCLAIMER | PRIVACY POLICY | TERMS AND CONDITIONS |  |